Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

    Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., dqp123, dqp123, Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., Holmström, M. O., Hendel, Helle Westergren, Ehrnrooth, E., Zocca, M. B., Pedersen, A. W., Andersen, Mads Hald & Svane, Inge Marie, 2021, In: Nature Medicine. 27, p. pages2212–2223

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

    Morgan Hulen , T., Chamberlain, C. A., Svane, Inge Marie & Met, Özcan, 2021, In: Immuno. 1, 3, p. 194-211

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

    Klausen, U., Grønne Dahlager Jørgensen, N., Grauslund, J. H., Munir Ahmad, S., Gang, Anne Ortved, Martinenaite, E., Weis-Banke, S. E., Breinholt, M. F., Novotny, G. W., Kjeldsen, J. W., Orebo Holmström, M., Pedersen, L. B., Poulsen, C. B., Hansen, P. B., Met, Özcan, Svane, Inge Marie, Niemann, Carsten, Pedersen, Lars Møller & Andersen, Mads Hald, 2021, In: OncoImmunology. 10, 1, 1975889.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition

    Kverneland, Anders Handrup, Borch, T. H., Granhøj, J., Sengeløv, Henrik, Donia, M. & Svane, Inge Marie, Aug 2021, In: Cytotherapy. 23, 8, p. 724-729 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

    Borch, T. H., Harbst, K., Rana, A. H., Andersen, R., Martinenaite, E., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J. W., Kverneland, Anders Handrup, Lauss, M., Hølmich, Lisbet Rosenkrantz, Hendel, Helle Westergren, Met, Özcan, Jönsson, G., dqp123, dqp123 & Svane, Inge Marie, 2021, In: Journal for ImmunoTherapy of Cancer. 9, 7, 15 p., e00270.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Comparison of efficacy in patients with metastatic melanoma treated with ipilimumab and nivolumab who did or did not discontinue treatment due to immune-related adverse events: A real-world data study

    Fink, M., Vittrup, A. S., Bastholt, L., Svane, Inge Marie, dqp123, dqp123, Luczak, A. A., Ruhlmann, C. H., Guldbrandt, L. M., Koehler, U. H., Winther, M. L., Ellebaek, E., Haslund, C. A. & Schmidt, H., 2021, In: Cancers. 13, 21, 10 p., 5550.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    Eggermont, A. M. M., Meshcheryakov, A., Atkinson, V., Blank, C. U., Mandala, M., Long, G. V., Barrow, C., Di Giacomo, A. M., Fisher, R., Sandhu, S., Kudchadkar, R., Romero, P. L. O., Svane, I. M., Larkin, J., Puig, S., Hersey, P., Quaglino, P., Queirolo, P., Stroyakovskiy, D., Bastholt, L. & 14 others, Mohr, P., Hernberg, M., Chiarion-Sileni, V., Strother, M., Hauschild, A., Yamazaki, N., van Akkooi, A. C., Lorigan, P., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S. & Robert, C., 2021, In: European Journal of Cancer. 158, p. 156-168 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

    Holmström, M. O., Mortensen, R. E. J., Pavlidis, A. M., Martinenaite, E., Weis-Banke, S. E., Aaboe-Jørgensen, M., Bendtsen, S. K., Met, Özcan, Pedersen, A. W., Donia, M., Svane, Inge Marie & Andersen, Mads Hald, Feb 2021, In: Cellular and Molecular Immunology. 18, 2, p. 415-426 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer

    D’souza, M., Svane, Inge Marie, Gislason, Gunnar Hilmar & Schou, Morten, 21 Apr 2021, In: European Heart Journal. 42, 16, p. 1636-1636 1 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

Previous 1 2 3 Next

ID: 4054758